库欣病新疗法:Isturisa(osilodrostat)获得美国FDA批准

2020-03-09 Allan MedSci原创

美国FDA今日批准了Isturisa(osilodrostat)口服片剂用于治疗成人库欣氏病,这些成年患者要么不能进行垂体手术,要么已经进行了手术但仍然患有这种疾病。

美国FDA今日批准了Isturisa(osilodrostat)口服片剂用于治疗成人库欣氏病,这些成年患者要么不能进行垂体手术,要么已经进行了手术但仍然患有这种疾病。库欣病是一种罕见的疾病,患者肾上腺分泌过多的皮质醇激素。Isturisa是第一种通过FDA批准的药物,可通过阻断11-β-羟化酶进而阻止皮质醇激素的合成。FDA药物评估和研究中心主任,医学博士Mary Thanh Hai说:“FDA支持开发针对罕见疾病的安全有效的疗法,Isturisa能够帮助患者达到正常的皮质醇水平,这种药物对于成人库欣病是重要的治疗选择”。

库欣病是多由垂体瘤引起,垂体瘤释放出过多的肾上腺皮质激素,该激素刺激肾上腺产生过量的皮质醇。该病最常见于30至50岁之间的成年人,对女性的影响是男性的三倍。库欣病会引起严重的健康问题,例如高血压、肥胖、2型糖尿病、腿和肺部血块、骨质流失和骨折、免疫力下降和抑郁。

 

原始出处:

https://www.firstwordpharma.com/node/1706578

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839779, encodeId=d2aa1839e793d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jun 12 16:05:18 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364573, encodeId=cafe13645e3cb, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385375, encodeId=761f13853e5ef, content=<a href='/topic/show?id=e38b492447d' target=_blank style='color:#2F92EE;'>#库欣病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49244, encryptionId=e38b492447d, topicName=库欣病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551470, encodeId=0f4415514e02d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554575, encodeId=c49215545e5a2, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=)]
    2020-06-12 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839779, encodeId=d2aa1839e793d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jun 12 16:05:18 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364573, encodeId=cafe13645e3cb, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385375, encodeId=761f13853e5ef, content=<a href='/topic/show?id=e38b492447d' target=_blank style='color:#2F92EE;'>#库欣病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49244, encryptionId=e38b492447d, topicName=库欣病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551470, encodeId=0f4415514e02d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554575, encodeId=c49215545e5a2, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=)]
    2020-03-11 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839779, encodeId=d2aa1839e793d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jun 12 16:05:18 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364573, encodeId=cafe13645e3cb, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385375, encodeId=761f13853e5ef, content=<a href='/topic/show?id=e38b492447d' target=_blank style='color:#2F92EE;'>#库欣病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49244, encryptionId=e38b492447d, topicName=库欣病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551470, encodeId=0f4415514e02d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554575, encodeId=c49215545e5a2, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839779, encodeId=d2aa1839e793d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jun 12 16:05:18 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364573, encodeId=cafe13645e3cb, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385375, encodeId=761f13853e5ef, content=<a href='/topic/show?id=e38b492447d' target=_blank style='color:#2F92EE;'>#库欣病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49244, encryptionId=e38b492447d, topicName=库欣病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551470, encodeId=0f4415514e02d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554575, encodeId=c49215545e5a2, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1839779, encodeId=d2aa1839e793d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jun 12 16:05:18 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364573, encodeId=cafe13645e3cb, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385375, encodeId=761f13853e5ef, content=<a href='/topic/show?id=e38b492447d' target=_blank style='color:#2F92EE;'>#库欣病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49244, encryptionId=e38b492447d, topicName=库欣病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551470, encodeId=0f4415514e02d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554575, encodeId=c49215545e5a2, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Wed Mar 11 03:05:18 CST 2020, time=2020-03-11, status=1, ipAttribution=)]
    2020-03-11 kcb074

相关资讯

膀胱过度活动症的治疗取得新进展!FDA接受Vibegron的新药申请(NDA)

Urovant Sciences今日宣布,美国食品药品监督管理局(FDA)已接受该公司候选药物Vibegron的新药申请(NDA),以治疗膀胱过度活动症(OAB)患者的急迫性尿失禁、尿急和尿频的症状。

EHP的大麻双酚衍生物口服制剂EFDA-101治疗系统性硬化症,获得美国FDA的快速通道指定

Emerald Health Pharmaceuticals(EHP)临床主要候选产品EHP-101,获得了美国食品和药物管理局的快速通道认证,用于治疗系统性硬化症(SSc)。

美国FDA批准新一代抗CTLA-4抗体HBM4003治疗癌症的IND

Harbor BioMed近日宣布,美国FDA批准了新一代抗CTLA-4抗体HBM4003治疗晚期实体瘤的研究性新药申请(IND),以开始进行临床研究。

美国国会施压,前FDA局长或出任COVID-19工作组负责人!

尽管中国报告的新病例数量已趋于平稳,但随着更多其他国家报告病例增加,新型冠状病毒肺炎(COVID-19)疫情不容乐观。美国疾控中心警告,新冠病毒可能将在美国变得更加普遍。

美国FDA批准RV001治疗晚期前列腺癌的IIb期临床试验

RhoVac制药公司近日宣布,2020年2月28日,美国食品药品监督管理局(FDA)批准了RV001的研究性新药申请(IND),以启动RV001治疗晚期前列腺癌的IIb期临床试验。

FDA批准赛诺菲靶向CD38的单抗Sarclisa,用于治疗复发或难治的多发性骨髓瘤

美国食品和药物管理局已批准赛诺菲的Sarclisa(isatuximab-irfc)用于治疗多发性骨髓瘤。该药物靶向骨髓瘤细胞表面的CD38蛋白发挥作用,这是继强生公司的Darzalex(daratumumab)获批之后第二个靶向CD38蛋白的药物。

拓展阅读

JCEM:Osilodrostat治疗库欣病的随机试验

长期暴露于皮质醇水平升高的环境中,会导致发病率和死亡率显著增加,生活质量(QoL)受损。因此,皮质醇的正常化是库欣病的主要治疗目标。经蝶手术是大多数患者的一线治疗方法。

Lancet Diabetes Endo:Osilodrostat治疗库欣病III期临床获得成功

研究认为,osilodrostat可减少库欣病患者尿游离皮质醇含量,且耐受性良好

Acta Neuropathologica:全基因组DNA甲基化谱可区分静默和非静默性ACTH腺瘤

糖皮质激素腺瘤表达肾上腺皮质营养激素(ACTH),可能会导致库欣病(CD)。表达ACTH但不引起皮质醇过多的沉默ACTH腺瘤(SCA)可能表现出更具侵袭性的病程,根据WHO的分类,目前被归类为&ldq

Pituitary:垂体腺瘤切除术后检测ACTH或可准确预测库欣病缓解

根据发表在Pituitary上的一项研究,在垂体腺瘤切除术后不久进行血浆促肾上腺皮质激素(ACTH)抑制试验或可准确预测库欣病的短期和长期缓解。

JCEM:立体定向放射外科治疗库欣病

大家都知道由于ACTH分泌的垂体瘤引起的库欣病(CD)的管理一直还存在挑战,而为了更好的了解立体定向放射治疗(SRS)对于CD的疗效及在管理中的作用,Gautam U Mehta等人进行了一项国际、多中心、回顾性队列分析,并将结果发表在近日的JCEM杂志上。

JCEM:库欣病患者术后评估:去氨加压素试验 vs 皮质醇水平

成功经蝶窦手术(TSS)治疗库欣病(CD)后,CD的复发率较高。很多CD患者表现出异常的去氨加压素试验(DT)。术后这种反应的消失,可能暗示异常促肾上腺皮质激素细胞的完全切除和更低的复发可能性。 本项回顾性研究,比较术后DT vs.术后皮质醇(Cort)水平,对患者长期结局的预测。 研究纳入了73名进行TSS和术后DT的患者,51例出现持续缓解(定义:6个月时,地塞米松抑制试验和UFC